This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Biotech

Pharmacyclics (PCYC) Stock Spikes Today Following $21 Billion AbbVie Merger Deal

Pharmacyclics (PCYC) Stock Spikes Today Following $21 Billion AbbVie Merger Deal

  • Tickers in this article:
  • PCYC

Pharmacyclics (PCYC) shares are up double digits after the company announced that it was purchased by AbbVie (ABBV) for $21 billion.

03/05/15 - 10:56 AM EST

AbbVie to Acquire Pharmacyclics: What Wall Street's Saying

Shares of Pharmacyclics surge after AbbVie announces plans to acquire the maker of leukemia drugs for $21 billion.

03/05/15 - 10:47 AM EST

Bristol-Myers Squibb (BMY) Stock Continues Climb Today on $975M Prostate Cancer Vaccine Deal

Bristol-Myers Squibb (BMY) Stock Continues Climb Today on $975M Prostate Cancer Vaccine Deal

  • Tickers in this article:
  • BMY

Bristol-Myers Squibb (BMY) shares are gaining a day after reaching a 14-year high after the company inked a $975 million deal for an experimental prostate cancer vaccine.

03/05/15 - 10:21 AM EST

AbbVie Buys Pharmacyclics for $21B to Get Half of Big Cancer Drug

AbbVie Buys Pharmacyclics for $21B to Get Half of Big Cancer Drug

AbbVie announced it is buying cancer drug-maker Pharmacyclics for $21 billion.

03/05/15 - 10:05 AM EST

AbbVie Spending Historic Amount of Cash to Buy Half of a Cancer Drug

AbbVie Spending Historic Amount of Cash to Buy Half of a Cancer Drug

The $21 billion price tag for Pharmacylics only earns AbbVie rights to 50% of the blood cancer drug Imbruvica.

03/05/15 - 06:38 AM EST

Credit Suisse: 8 Biotech and Health Care Stocks Add to Your Portfolio Right Now

Credit Suisse: 8 Biotech and Health Care Stocks Add to Your Portfolio Right Now

Biotechnology and health care in general are some of the hottest areas for investment these days.

03/05/15 - 08:58 AM EST

Alcoa Drops on Bank of America Downgrade as Dow Drops Triple Digits

Alcoa Drops on Bank of America Downgrade as Dow Drops Triple Digits

A down day for U.S. markets Wednesday with the Dow dropping triple digits.

03/04/15 - 04:35 PM EST

Regulators Want Drug Companies to Be Honest About FDA

Regulators Want Drug Companies to Be Honest About FDA

The Securities and Exchange Commission's top cop wants drug companies to be more transparent with investors about their dealings with the U.S. Food and Drug Administration.

03/04/15 - 01:08 PM EST

Bristol-Myers' Cancer Immunotherapy Opdivo Wins Approval to Treat Lung Cancer

Bristol-Myers' Cancer Immunotherapy Opdivo Wins Approval to Treat Lung Cancer

  • Tickers in this article:
  • BMY

The new Opdivo approval covers patients with squamous non-small cell lung cancer no longer responsive to chemotherapy, according to an announcement made the FDA.

03/04/15 - 01:47 PM EST

MannKind's Charts Suggest Waiting on the Stock After Goldman's Downgrade

MannKind's Charts Suggest Waiting on the Stock After Goldman's Downgrade

  • Tickers in this article:
  • MNKD

Here's a technical look at the stock after a brutal downgrade.

03/03/15 - 04:22 PM EST

Orexigen Weight-Loss Pill Shows Surprise Heart-Safety Benefit

Orexigen Weight-Loss Pill Shows Surprise Heart-Safety Benefit

Obese Americans taking Contrave to lose weight cut their risk of having a heart attack, stroke or dying from heart disease by almost half compared to people taking a placebo.

03/03/15 - 11:51 AM EST

Cramer: Goldman's Negative MannKind Report Creates 'Problematic Situation'

Cramer: Goldman's Negative MannKind Report Creates 'Problematic Situation'

  • Tickers in this article:
  • MNKD

Cramer says the negative Goldman Sachs is having an unhealthy effect on MannKind's stock.

03/03/15 - 11:28 AM EST

MannKind Rating, Price Target Are Cut by Goldman on Slow Afrezza Launch

MannKind Rating, Price Target Are Cut by Goldman on Slow Afrezza Launch

  • Tickers in this article:
  • MNKD
  • SNY

The slow commercial launch of the inhaled insulin Afrezza coupled with growing downward pricing pressure for all diabetes products compels Goldman Sachs to slap a 'sell' rating on MannKind.

03/03/15 - 08:16 AM EST

March Mergers Take Off With Multi-Billion Tech, Healthcare Deals

March Mergers Take Off With Multi-Billion Tech, Healthcare Deals

March madness has nothing on Wall Street as the first Monday in the month kicks off with several multi-billion dollar deals.

03/02/15 - 01:08 PM EST

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 18,120.66 +23.76 0.13%
S&P 500 2,101.15 +2.62 0.12%
NASDAQ 4,981.7590 +14.6180 0.29%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs